StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
SunTrust Weighs in Dr. Fauci's Summary of NIAID Data on Gilead (GILD) Remdesivir
April 29, 2020 1:37 PM
SunTrust analyst Robyn Karnauskas weighed in on Gilead Sciences (NASDAQ: GILD) remdesivir after Dr. Fauci provided NIAID data, which was ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Despite 'Crazy Data Points' Gilead's (GILD) Remdesivir Could Be Approved as Soon as Today - Baird
April 29, 2020 1:16 PM
Gilead Sciences (GILD) Pushes to Session Highs; Up 8%
April 29, 2020 12:53 PM
Fauci Says Data Shows Gilead's (GILD) Remdesivir has Clear Cut Positive Effect on Virus - Bloomberg
April 29, 2020 11:55 AM
Raymond James Said 'Let's Not Overreact' to Today's Gilead Sciences (GILD) Data
April 29, 2020 11:47 AM
Gilead (GILD) Rembesivir Failed in First Clinical Trial From China, Study Published in Lancet - Reports
April 29, 2020 11:17 AM
Gilead Sciences (GILD) call put ratio 3 calls to 1 put into quarter results
April 29, 2020 10:52 AM
U.S. NIH to Release Gilead (GILD) Virus Drug Trial Results Later Today, Likely to be Released at White House Event - Bloomberg
April 29, 2020 10:51 AM
FDA in Talks to Make Remdesivir Available as Appropriate, Agency Talking with Gilead (GILD) to Get Drug to Patients Quickly - Bloomberg, Citing Email
April 29, 2020 10:15 AM
Gilead Sciences (GILD) gains 8% as trading resumes
April 29, 2020 9:00 AM
Gilead Sciences (GILD) to resume trading at 9:00AM ET
April 29, 2020 8:40 AM
Gilead Sciences (GILD) Phase 3 Trial of Remdesivir in Severe COVID-19 Patients Shows Improvement
April 29, 2020 8:38 AM
Gilead Sciences (GILD) IV at 73 into positive remdesivir results
April 29, 2020 8:38 AM
Stock futures add to gains amid positive Gilead remdesivir results
April 29, 2020 8:35 AM
Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
April 29, 2020 8:35 AM
Gilead (GILD) Says NIAID Study of Investigational Antiviral Remdesivir for COVID-19 Met Its Primary Endpoint
April 29, 2020 8:30 AM
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19
April 29, 2020 8:30 AM
